Market Overview:
The global Crohn's disease drug market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of Crohn's disease, rising awareness about Crohn's disease, and technological advancements in the field of drug development. The global Crohn's disease drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into aminosalicylates (5-ASA), corticosteroids, immunomodulators, and antibiotics. On the basis of application, the market is divided into achieving remission (the absence of symptoms), maintaining remission (prevention of flare-ups), and pediatric Crohn'S disease. Geographically, this market has been segmented into North America,, Latin America,, Europe,, Asia Pacific,, Middle East & Africa,.
Product Definition:
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus. Symptoms can range from mild, such as abdominal pain and cramping, to severe, such as debilitating diarrhea and weight loss. Crohn's disease drug is important because it can help reduce symptoms and improve quality of life for people with the condition.
Aminosalicylates (5-ASA):
Aminosalicylates (5-ASA) is a group of medication used for the treatment of Inflammatory Bowel Disease (IBD), also called Crohn's disease. It works by reducing the activity of salicylic acid, which causes inflammation. The drug has been in use since the early 70s and was approved by FDA in 1974 as 5-aminolevulinic acid; it received U.S.
Corticosteroids:
Corticosteroids are the group of drugs that act as anti-inflammatory agents. Corticosteroid medication is used to reduce inflammation in the body, and it works by decreasing leukocytes (white blood cells) production. Corticosteroids can be administered orally or topically (by mouth or nose). They are available as tablets, injections, nasal sprays, and eye drops.
Application Insights:
The achieving remission segment dominated the global market in 2017, owing to an increase in the number of patients reaching clinical remission. Clinical remission is a significant step forward towards healing and does not represent final goal. Achieving this stage requires further investigation for identifying trigger factors responsible for relapses and designing effective treatment plans.
In order to maintain clinical stability, ongoing therapy with anti-inflammatory drugs or immunosuppressive drugs is required during Crohn’s disease maintaining period (the time span from when patient achieves clinical remission until next flare-up). However, due to increasing awareness about maintaining permanent relief without having any relapses or flares up; achieving permanent relief has become more difficult compared to before.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of pharmaceutical companies, availability of advanced healthcare facilities and favorable reimbursement policies are some factors responsible for its dominance. In addition, increasing prevalence of IBD is also expected to contribute towards its growth over the forecast period.
Asia Pacific is expected to grow at the fastest rate during the forecast period due to rising disposable income and improving healthcare infrastructure especially in emerging countries such as India and China.
Growth Factors:
- Increasing incidence of Crohn's disease
- Growing awareness about the disease
- Rising demand for better treatment options
- Technological advancements in drug delivery systems
- Availability of government funding for research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Crohn’s Disease Drug Market Research Report
By Type
Aminosalicylates (5-ASA), Corticosteroids, Immunomodulators, Antibiotics
By Application
Achieving Remission (The Absence Of Symptoms), Maintaining Remission (Prevention Of Flare-Ups), Pediatric Crohn'S Disease
By Companies
AbbVie, Janssen Biotech, Amgen, Tillotts Pharma, Takeda Pharmaceuticals, AbbVie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Crohn’s Disease Drug Market Report Segments:
The global Crohn’s Disease Drug market is segmented on the basis of:
Types
Aminosalicylates (5-ASA), Corticosteroids, Immunomodulators, Antibiotics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Achieving Remission (The Absence Of Symptoms), Maintaining Remission (Prevention Of Flare-Ups), Pediatric Crohn'S Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Janssen Biotech
- Amgen
- Tillotts Pharma
- Takeda Pharmaceuticals
- AbbVie
Highlights of The Crohn’s Disease Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aminosalicylates (5-ASA)
- Corticosteroids
- Immunomodulators
- Antibiotics
- By Application:
- Achieving Remission (The Absence Of Symptoms)
- Maintaining Remission (Prevention Of Flare-Ups)
- Pediatric Crohn'S Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Crohn’s Disease Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Crohnu00e2u20acu2122s disease drug is a medication used to treat Crohnu00e2u20acu2122s disease.
Some of the major companies in the crohn’s disease drug market are AbbVie, Janssen Biotech, Amgen, Tillotts Pharma, Takeda Pharmaceuticals, AbbVie.
The crohn¢‚¬„¢s disease drug market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Crohn’s Disease Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Crohn’s Disease Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Crohn’s Disease Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Crohn’s Disease Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Crohn’s Disease Drug Market Size & Forecast, 2018-2028
4.5.1 Crohn’s Disease Drug Market Size and Y-o-Y Growth
4.5.2 Crohn’s Disease Drug Market Absolute $ Opportunity
Chapter 5 Global Crohn’s Disease Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Crohn’s Disease Drug Market Size Forecast by Type
5.2.1 Aminosalicylates (5-ASA)
5.2.2 Corticosteroids
5.2.3 Immunomodulators
5.2.4 Antibiotics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Crohn’s Disease Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Crohn’s Disease Drug Market Size Forecast by Applications
6.2.1 Achieving Remission (The Absence Of Symptoms)
6.2.2 Maintaining Remission (Prevention Of Flare-Ups)
6.2.3 Pediatric Crohn'S Disease
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Crohn’s Disease Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Crohn’s Disease Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Crohn’s Disease Drug Analysis and Forecast
9.1 Introduction
9.2 North America Crohn’s Disease Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Crohn’s Disease Drug Market Size Forecast by Type
9.6.1 Aminosalicylates (5-ASA)
9.6.2 Corticosteroids
9.6.3 Immunomodulators
9.6.4 Antibiotics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Crohn’s Disease Drug Market Size Forecast by Applications
9.10.1 Achieving Remission (The Absence Of Symptoms)
9.10.2 Maintaining Remission (Prevention Of Flare-Ups)
9.10.3 Pediatric Crohn'S Disease
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Crohn’s Disease Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Crohn’s Disease Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Crohn’s Disease Drug Market Size Forecast by Type
10.6.1 Aminosalicylates (5-ASA)
10.6.2 Corticosteroids
10.6.3 Immunomodulators
10.6.4 Antibiotics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Crohn’s Disease Drug Market Size Forecast by Applications
10.10.1 Achieving Remission (The Absence Of Symptoms)
10.10.2 Maintaining Remission (Prevention Of Flare-Ups)
10.10.3 Pediatric Crohn'S Disease
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Crohn’s Disease Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Crohn’s Disease Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Crohn’s Disease Drug Market Size Forecast by Type
11.6.1 Aminosalicylates (5-ASA)
11.6.2 Corticosteroids
11.6.3 Immunomodulators
11.6.4 Antibiotics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Crohn’s Disease Drug Market Size Forecast by Applications
11.10.1 Achieving Remission (The Absence Of Symptoms)
11.10.2 Maintaining Remission (Prevention Of Flare-Ups)
11.10.3 Pediatric Crohn'S Disease
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Crohn’s Disease Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Crohn’s Disease Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Crohn’s Disease Drug Market Size Forecast by Type
12.6.1 Aminosalicylates (5-ASA)
12.6.2 Corticosteroids
12.6.3 Immunomodulators
12.6.4 Antibiotics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Crohn’s Disease Drug Market Size Forecast by Applications
12.10.1 Achieving Remission (The Absence Of Symptoms)
12.10.2 Maintaining Remission (Prevention Of Flare-Ups)
12.10.3 Pediatric Crohn'S Disease
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Crohn’s Disease Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Crohn’s Disease Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Crohn’s Disease Drug Market Size Forecast by Type
13.6.1 Aminosalicylates (5-ASA)
13.6.2 Corticosteroids
13.6.3 Immunomodulators
13.6.4 Antibiotics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Crohn’s Disease Drug Market Size Forecast by Applications
13.10.1 Achieving Remission (The Absence Of Symptoms)
13.10.2 Maintaining Remission (Prevention Of Flare-Ups)
13.10.3 Pediatric Crohn'S Disease
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Crohn’s Disease Drug Market: Competitive Dashboard
14.2 Global Crohn’s Disease Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Janssen Biotech
14.3.3 Amgen
14.3.4 Tillotts Pharma
14.3.5 Takeda Pharmaceuticals
14.3.6 AbbVie
